The authors report a case of Listeria monocytogenes septicemia in a patient with advanced CLL after a single course of fludarabine, without any other immunosuppressive therapy e.g. corticosteroids. The immunosuppressive action of fludarabine in patients who are already severely immunosuppressed must be considered from a diagnostic and therapeutic point of view. Listeriosis and other opportunistic infections, like pneumocystis carinii pneumonia, have been reported during and after treatment with purine analogues. Prophylaxis with cotrimoxazole must therefore be discussed in patients with CLL treated with fludarabine.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00282-997-0089-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report.
Ann Hematol
September 2001
Department of Hematology, Singapore General Hospital, Singapore.
Chronic hepatitis B infection poses a problem in patients with malignancies undergoing chemotherapy. Not uncommonly, hepatitis B virus (HBV) reactivates during or soon after chemotherapy. We report a case of a woman with acute prolymphocytic leukemia who received chemotherapy containing fludarabine and cyclophosphamide, followed by the CD 20 monoclonal antibody, rituximab.
View Article and Find Full Text PDFInfections in patients with chronic lymphocytic leukemia treated with fludarabine.
Ann Intern Med
October 1998
University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.
Background: Fludarabine, a purine analogue with activity in chronic lymphocytic leukemia, is usually well tolerated. Although serious infections after fludarabine therapy have been described, a systematic analysis of the risk factors for such infections in chronic lymphocytic leukemia is lacking.
Objective: To determine the risk factors for major infection in patients with chronic lymphocytic leukemia treated with fludarabine.
Opportunistic infections have been a problem after BMT in CLL. We have allografted seven patients with B-CLL (n = 6) or B-prolymphocytic leukemia (n = 1) from matched siblings (n = 6) or a mismatched unrelated donor (n = 1). Amongst the first six, we saw two cases of recurrent or prolonged cytomegaloviremia and CMV disease, one listeria meningitis, and one fatal toxoplasma encephalitis.
View Article and Find Full Text PDFPresent status of purine analogs in the therapy of chronic lymphocytic leukemias.
Leukemia
April 1997
Medical Clinic III, University Hospital, JW Goethe University, Frankfurt, Germany.
Chronic lymphocytic leukemia (CLL) is considered an incurable disease and therefore the management is palliative and more disease-related symptoms directed. Recently, the high activity of nucleoside analogs as fludarabine (FAMP), 2-chlorodeoxyadenosine (2-CDA) and 2-deoxycoformycin (DCF) in low-grade NHLs has caused a new reawakening interest in CLL concerning new treatment strategies, the biology and prognostic factors of this disease. Predominantly FAMP has widely been studied in CLL with impressive remission rates of 30-70%, including some complete remission (CR) in refractory or relapsed CLL.
View Article and Find Full Text PDFListeriosis after fludarabine treatment for chronic lymphocytic leukemia.
Hematol Cell Ther
April 1997
Department of Oncology/Haematology, HIA Sainte-Anne, Toulon Naval, France.
The authors report a case of Listeria monocytogenes septicemia in a patient with advanced CLL after a single course of fludarabine, without any other immunosuppressive therapy e.g. corticosteroids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!